First line choice in melanoma: immunotherapy or target therapy? We asked Omid Hamid, Director of Melanoma Therapeutics of The Angeles Clinic and Research Institute of Santa Monica. And what about monotherapy? In which patients we could use this therapeutical approach? From the Immunotherapy & Melanoma Bridge 2017 held in Naples.
Combination immunotherapy, yes. But what combination? That is the important question.
Director of Melanoma Therapeutics The Angeles Clinic and Research Institute, Santa Monica
Napoli, 1 dicembre 2017 Intervista a cura di Giulia Volpe